Denosumab side effects: what 201,340 FDA adverse event reports show
Drug class
RANK Ligand Inhibitor
Brand names
Jubbonti
Who reports
201,340 reports · 54% serious · 25,732 with death outcome · 84% female
Used for
Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture.
What it is
Denosumab-bbdz is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab-bbdz has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
Boxed warning
SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE • Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,183 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Bone giant cell tumour | 307 | 405.7 316.1–520.8ROR 406.3 · calibrated p 1e-12 ✓ | 81.8 EB05 74.4 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=307 · ♀ 54% (drug 84%) · 100% clinician | not reported in cached trials |
| Exostosis of jaw | 289 | 150.8 125.8–180.8ROR 151.0 · calibrated p 6e-9 ✓ | 61.1 EB05 55.4 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=206 | not reported in cached trials |
| Osteonecrosis of external auditory canal | 90 | 95.4 71.6–127.2ROR 95.4 · calibrated p 3e-7 ✓ | 49.2 EB05 41.3 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=90 · 100% clinician | not reported in cached trials |
| Atypical fracture | 225 | 60.3 51.1–71.1ROR 60.3 · calibrated p 5e-6 ✓ | 38.1 EB05 34.1 · IC025 +4.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=224 · 100% clinician | not reported in cached trials |
| Osteonecrosis of jaw (jawbone death) | 8,645 | 55.2 53.7–56.6ROR 57.6 · calibrated p 5e-6 ✓ | 36.1 EB05 35.5 · IC025 +5.1 3/3 methods agree | Labeled — boxed warning synonym match | serious PRR 38.3 | NCT00089791: 2/3,886 (0.1%) on Denosumab; 1/3,876 (0.0%) control (serious AE) |
| Atypical femur fracture | 881 | 46.7 43.1–50.6ROR 46.9 · calibrated p 2e-5 ✓ | 32.3 EB05 30.6 · IC025 +4.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=879 | not reported in cached trials |
| Dental care | 566 | 45.7 41.4–50.5ROR 45.8 · calibrated p 2e-5 ✓ | 31.8 EB05 29.7 · IC025 +4.8 3/3 methods agree | Labeled (related wording) related wording | serious n=179 | not reported in cached trials |
| Tooth resorption | 63 | 44.8 33.3–60.3ROR 44.8 · calibrated p 4e-5 ✓ | 31.2 EB05 25.2 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | 100% consumer | not reported in cached trials |
| Dental implantation | 409 | 34.7 31.0–38.8ROR 34.7 · calibrated p 1e-4 ✓ | 26.1 EB05 24.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=203 | not reported in cached trials |
| Oestrogen deficiency | 69 | 34.6 26.3–45.5ROR 34.6 · calibrated p 2e-4 ✓ | 25.9 EB05 21.2 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=52 · 100% consumer | not reported in cached trials |
| Artificial crown procedure | 119 | 32.7 26.6–40.2ROR 32.7 · calibrated p 2e-4 ✓ | 24.9 EB05 21.4 · IC025 +4.2 3/3 methods agree | Reporting / coding artifact | – | not reported in cached trials |
| Pik3ca-activated mutation | 75 | 30.9 23.9–40.0ROR 30.9 · calibrated p 3e-4 ✓ | 23.8 EB05 19.6 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=75 · 100% clinician | not reported in cached trials |
| Thoracic vertebral fracture | 648 | 29.2 26.8–31.9ROR 29.3 · calibrated p 3e-4 ✓ | 22.9 EB05 21.5 · IC025 +4.4 3/3 methods agree | Labeled (related wording) related wording | serious n=644 | NCT00089791: 1/3,886 (0.0%) on Denosumab; 9/3,876 (0.2%) control (serious AE) |
| Dental restoration failure | 151 | 27.4 22.9–32.8ROR 27.4 · calibrated p 5e-4 ✓ | 21.7 EB05 19.0 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=71 | not reported in cached trials |
| Exposed bone in jaw | 436 | 25.7 23.1–28.6ROR 25.8 · calibrated p 6e-4 ✓ | 20.7 EB05 19.1 · IC025 +4.2 3/3 methods agree | Labeled (related wording) related wording | serious n=422 | not reported in cached trials |
| Bone density abnormal | 717 | 24.3 22.4–26.3ROR 24.3 · calibrated p 8e-4 ✓ | 19.8 EB05 18.6 · IC025 +4.2 3/3 methods agree | Lab value / disease marker | serious n=179 | not reported in cached trials |
| Blood parathyroid hormone increased | 551 | 24.0 21.9–26.4ROR 24.1 · calibrated p 8e-4 ✓ | 19.6 EB05 18.3 · IC025 +4.1 3/3 methods agree | Lab value / disease marker | serious n=333 | not reported in cached trials |
| Carbohydrate antigen 15-3 increased | 138 | 22.9 19.0–27.5ROR 22.9 · calibrated p 0.001 ✓ | 18.8 EB05 16.3 · IC025 +3.9 3/3 methods agree | Lab value / disease marker | serious n=137 · 100% clinician | not reported in cached trials |
| Hypocalcaemia (low calcium) | 3,338 | 22.2 21.4–23.1ROR 22.6 · calibrated p 0.001 ✓ | 18.4 EB05 17.9 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 14.7 · serious PRR 17.6 · ♀ 61% (drug 84%) | NCT00089791: 1/3,876 (0.0%) control (serious AE) |
| Jaw operation | 156 | 21.9 18.4–26.1ROR 21.9 · calibrated p 0.001 ✓ | 18.2 EB05 15.9 · IC025 +3.8 3/3 methods agree | Reporting / coding artifact | serious n=155 | NCT01575834: 1/3,581 (0.0%) on Denosumab (serious AE) |
| Jaw disorder | 949 | 21.4 20.0–23.0ROR 21.5 · calibrated p 0.001 ✓ | 17.9 EB05 16.9 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=445 | not reported in cached trials |
| Pathological fracture | 825 | 20.0 18.6–21.6ROR 20.1 · calibrated p 0.002 ✓ | 16.9 EB05 16.0 · IC025 +4.0 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=822 | not reported in cached trials |
| Intercepted product administration error | 1,212 | 19.3 18.1–20.5ROR 19.4 · calibrated p 0.002 ✓ | 16.3 EB05 15.6 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | – | not reported in cached trials |
| Abscess jaw | 162 | 18.8 15.9–22.3ROR 18.9 · calibrated p 0.003 ✓ | 16.0 EB05 14.0 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=161 | NCT00089791: 2/3,886 (0.1%) on Denosumab (serious AE) |
| Dental fistula | 62 | 18.0 13.7–23.5ROR 18.0 · calibrated p 0.004 ✓ | 15.3 EB05 12.3 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=62 · 100% clinician | not reported in cached trials |
| Spinal fracture | 2,930 | 17.8 17.1–18.5ROR 18.1 · calibrated p 0.003 ✓ | 15.3 EB05 14.8 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious PRR 16.8 | NCT01575834: 2/3,581 (0.1%) on Denosumab; 3/3,576 (0.1%) control (serious AE) |
| Delusion of grandeur | 65 | 17.5 13.5–22.8ROR 17.6 · calibrated p 0.004 ✓ | 15.0 EB05 12.1 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=65 · ♀ 0% (drug 84%) · 100% clinician | not reported in cached trials |
| Tooth disorder | 3,234 | 17.5 16.8–18.1ROR 17.8 · calibrated p 0.003 ✓ | 15.1 EB05 14.6 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious PRR 10.8 | not reported in cached trials |
| Lumbar vertebral fracture | 639 | 16.9 15.6–18.4ROR 17.0 · calibrated p 0.004 ✓ | 14.6 EB05 13.7 · IC025 +3.7 3/3 methods agree | Labeled (related wording) related wording | serious n=636 | NCT00089791: 3/3,886 (0.1%) on Denosumab; 9/3,876 (0.2%) control (serious AE) |
| Loose tooth | 445 | 16.5 14.9–18.2ROR 16.5 · calibrated p 0.005 ✓ | 14.3 EB05 13.2 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=269 | not reported in cached trials |
| Osteoporotic fracture | 260 | 16.1 14.1–18.4ROR 16.1 · calibrated p 0.005 ✓ | 14.0 EB05 12.6 · IC025 +3.6 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=260 | not reported in cached trials |
| Blood calcium abnormal | 222 | 16.0 13.9–18.4ROR 16.0 · calibrated p 0.006 ✓ | 13.9 EB05 12.4 · IC025 +3.5 3/3 methods agree | Lab value / disease marker | serious n=109 | not reported in cached trials |
| Tooth extraction | 1,574 | 14.9 14.2–15.8ROR 15.1 · calibrated p 0.007 ✓ | 13.2 EB05 12.6 · IC025 +3.6 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 11.2 | not reported in cached trials |
| Spinal deformity | 213 | 14.8 12.9–17.1ROR 14.9 · calibrated p 0.008 ✓ | 13.0 EB05 11.6 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=189 · 74% consumer | not reported in cached trials |
| Endodontic procedure | 308 | 14.2 12.6–16.0ROR 14.3 · calibrated p 0.009 ✓ | 12.6 EB05 11.4 · IC025 +3.4 3/3 methods agree | Reporting / coding artifact | serious n=125 | not reported in cached trials |
| Traumatic fracture | 87 | 13.8 11.0–17.2ROR 13.8 · calibrated p 0.011 ✓ | 12.1 EB05 10.1 · IC025 +3.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=86 · 100% clinician | not reported in cached trials |
| Dental operation | 273 | 13.0 11.5–14.7ROR 13.0 · calibrated p 0.013 ✓ | 11.6 EB05 10.5 · IC025 +3.3 3/3 methods agree | Reporting / coding artifact | serious n=178 | not reported in cached trials |
| Sequestrectomy | 73 | 12.6 9.9–16.0ROR 12.6 · calibrated p 0.015 ✓ | 11.1 EB05 9.0 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=73 · 100% clinician | not reported in cached trials |
| Metastases to bone | 1,763 | 12.5 11.9–13.1ROR 12.6 · calibrated p 0.014 ✓ | 11.2 EB05 10.8 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 12.0 | NCT00089791: 1/3,886 (0.0%) on Denosumab; 1/3,876 (0.0%) control (serious AE) |
| Blood alkaline phosphatase decreased | 99 | 12.0 9.7–14.7ROR 12.0 · calibrated p 0.018 ✓ | 10.6 EB05 8.9 · IC025 +3.0 3/3 methods agree | Lab value / disease marker | 100% clinician | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Osteonecrosis | 9,340 | 20.019.5–20.4 | signal |
| Fall / fracture | 9,334 | 2.62.5–2.6 | signal |
| Neutropenia / agranulocytosis | 2,719 | 1.11.1–1.2 | raised |
| Anaemia | 3,035 | 1.11.0–1.1 | raised |
| Serious infection | 7,662 | 1.01.0–1.1 | raised |
| Tendon disorder | 371 | 1.00.9–1.1 | no difference |
| Interstitial lung disease | 896 | 1.00.9–1.0 | no difference |
| Thrombocytopenia | 1,859 | 0.90.8–0.9 | lower than other drugs |
| Malignancy | 3,112 | 0.90.8–0.9 | lower than other drugs |
| Arrhythmia / qt | 1,520 | 0.80.8–0.9 | lower than other drugs |
| Hyponatraemia | 609 | 0.80.7–0.9 | lower than other drugs |
| Opportunistic infection | 991 | 0.80.7–0.8 | lower than other drugs |
| Venous thromboembolism | 1,515 | 0.70.7–0.8 | lower than other drugs |
| Heart failure | 1,230 | 0.70.7–0.8 | lower than other drugs |
| Stroke | 1,535 | 0.60.6–0.7 | lower than other drugs |
| Kidney injury | 2,755 | 0.60.6–0.6 | lower than other drugs |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Denosumab as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (8 of 40 signal terms matched).
- NCT00089791 — A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis (N=7808, PHASE3; 893 AE terms posted; arms: Placebo; Denosumab 60 mg Q6M)
- NCT01575834 — Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (N=7180, PHASE3; 764 AE terms posted; arms: 12-Month Double-blind Period: Placebo; 12-Month Double-blind Period: Romosozuma; 36-Month Study Period: Placebo/Denosumab; 36-Month Study Period: Romosozumab/Denos)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Off label use (used outside approved label) | 36,716 | 4.6 4.5–4.6ROR 5.4 · calibrated p 0.200 | 4.4 EB05 4.4 · IC025 +2.1 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 4.4 · serious PRR 0.9 · 91% clinician | not reported in cached trials |
| Death | 20,353 | 2.5 2.5–2.5ROR 2.7 · calibrated p 0.746 | 2.5 EB05 2.4 · IC025 +1.3 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | age-adj. PRR 2.2 · serious PRR 2.6 | NCT00089791: 1/3,886 (0.0%) on Denosumab; 2/3,876 (0.1%) control (serious AE) |
| Arthralgia (joint pain) | 8,912 | 2.3 2.2–2.3ROR 2.3 · calibrated p 0.891 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.5 · serious PRR 2.1 | NCT00089791: 15/3,886 (0.4%) on Denosumab; 10/3,876 (0.3%) control (serious AE) |
| Osteonecrosis of jaw (jawbone death) | 8,645 | 55.2 53.7–56.6ROR 57.6 · calibrated p 5e-6 ✓ | 36.1 EB05 35.5 · IC025 +5.1 3/3 methods agree | Labeled — boxed warning synonym match | serious PRR 38.3 | NCT00089791: 2/3,886 (0.1%) on Denosumab; 1/3,876 (0.0%) control (serious AE) |
| Fatigue (tiredness) | 7,745 | 1.0 1.0–1.1ROR 1.0 · calibrated p 0.333 | 1.0 EB05 1.0 · IC025 +0.0 | Labeled (related wording) related wording | age-adj. PRR 1.1 · serious PRR 1.3 | NCT00089791: 1/3,886 (0.0%) on Denosumab; 1/3,876 (0.0%) control (serious AE) |
| Pain in extremity | 7,031 | 2.5 2.5–2.6ROR 2.6 · calibrated p 0.783 | 2.5 EB05 2.4 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.5 · serious PRR 2.3 | NCT00089791: 3/3,886 (0.1%) on Denosumab (serious AE) |
| Pain | 6,961 | 1.2 1.2–1.2ROR 1.2 · calibrated p 0.431 | 1.2 EB05 1.2 · IC025 +0.2 | Labeled — boxed warning exact term | age-adj. PRR 1.5 · serious PRR 1.1 | NCT00089791: 8/3,886 (0.2%) on Denosumab; 6/3,876 (0.2%) control (serious AE) |
| Back pain | 6,928 | 3.2 3.1–3.2ROR 3.2 · calibrated p 0.552 | 3.1 EB05 3.0 · IC025 +1.6 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.1 · serious PRR 2.8 | NCT00089791: 20/3,886 (0.5%) on Denosumab; 20/3,876 (0.5%) control (serious AE) |
| Nausea | 5,484 | 0.7 0.7–0.7ROR 0.7 · calibrated p 0.137 | 0.7 EB05 0.7 · IC025 -0.5 PRR-only: not supported by EBGM or IC | Not in label — unassessed | age-adj. PRR 0.8 · serious PRR 1.0 | NCT00089791: 5/3,886 (0.1%) on Denosumab; 5/3,876 (0.1%) control (serious AE) |
| Diarrhoea (diarrhea) | 5,338 | 0.9 0.8–0.9ROR 0.9 · calibrated p 0.218 | 0.9 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC | Not in label — unassessed | age-adj. PRR 0.8 · serious PRR 1.1 | NCT00089791: 6/3,886 (0.2%) on Denosumab; 8/3,876 (0.2%) control (serious AE) |
| Fall | 5,227 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.747 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.8 | NCT00089791: 16/3,886 (0.4%) on Denosumab; 18/3,876 (0.5%) control (serious AE) |
| Rash | 4,342 | 1.0 1.0–1.1ROR 1.0 · calibrated p 0.335 | 1.0 EB05 1.0 · IC025 +0.0 | Labeled adverse reaction exact term | age-adj. PRR 1.1 · serious PRR 1.1 | NCT00089791: 1/3,876 (0.0%) control (serious AE) |
| Myalgia (muscle pain) | 4,231 | 2.6 2.6–2.7ROR 2.7 · calibrated p 0.744 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.5 · serious PRR 2.1 | NCT00089791: 1/3,886 (0.0%) on Denosumab (serious AE) |
| Asthenia (weakness) | 4,084 | 1.1 1.1–1.2ROR 1.1 · calibrated p 0.396 | 1.1 EB05 1.1 · IC025 +0.1 | Labeled adverse reaction exact term | age-adj. PRR 1.0 · serious PRR 1.3 | NCT00089791: 4/3,886 (0.1%) on Denosumab (serious AE) |
| Bone pain | 4,043 | 7.6 7.4–7.9ROR 7.8 · calibrated p 0.072 | 7.2 EB05 7.0 · IC025 +2.8 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 7.2 · serious PRR 6.1 | NCT00089791: 4/3,886 (0.1%) on Denosumab; 1/3,876 (0.0%) control (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Bone giant cell tumour — n=307, PRR 405.7
- Exostosis of jaw — n=289, PRR 150.8
- Osteonecrosis of external auditory canal — n=90, PRR 95.4
- Tooth resorption — n=63, PRR 44.8
- Dental implantation — n=409, PRR 34.7
- Oestrogen deficiency — n=69, PRR 34.6
- Pik3ca-activated mutation — n=75, PRR 30.9
- Dental restoration failure — n=151, PRR 27.4
- Hypocalcaemia — n=3,338, PRR 22.2 (also seen in trial arm)
- Jaw disorder — n=949, PRR 21.4
✓ A hand-written Bradford Hill causality assessment exists for this drug: Denosumab ↔ Osteonecrosis of the jaw.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Denosumab?
In FDA FAERS, the most frequently co-reported reaction terms for Denosumab are arthralgia, osteonecrosis of jaw, fatigue, pain in extremity, pain, back pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Denosumab have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE • Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration.
Do FAERS signals prove that Denosumab causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 4bf239bb-c467-4add-b7cf-ea666e4fc693, effective 20251030; matched on
openfda.generic_name.exact:"DENOSUMAB" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,223 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
DENOSUMAB, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.